Gene Therapy Composition for Treating Eye Diseases

The European Patent Office published patent application EP4185333A1 by FTM GEN Corp for a gene therapy composition and method treating eye diseases. The application, filed by inventors SHI Zhongdong and ZHAO Wei, covers therapeutic applications using gene delivery technology (A61K 48/00). The designated states include all EU member states plus other European Economic Area countries.

Methods to Prevent SARS-CoV-2 Infection and Treat COVID-19

The European Patent Office published patent application EP4132967A2 for the University of Florida Research Foundation, covering methods and compositions to prevent SARS-CoV-2 infection and treat COVID-19. The patent claims specific methods using compositions classified under A61K 31/135, C07K 16/10, C12N 15/50, C07K 14/165, and A61K 39/215. This patent designation extends to all EPO member states including Germany, France, the United Kingdom, Italy, Spain, and 24 additional countries.

T Cell Progenitor Production Method

The European Patent Office published patent application EP4130253A1 for a T cell progenitor production method. Applicants are Kyoto University and Takeda Pharmaceutical Company Limited. The application covers methods for producing T cell progenitors for therapeutic applications, with IPC classifications in cell therapy and immunological preparations.

Method for Improving Plant Genetic Transformation and Gene Editing Efficiency

The European Patent Office published patent application EP4137577A1 for a method improving plant genetic transformation and gene editing efficiency. Applicants include the Institute of Genetics and Developmental Biology (Chinese Academy of Sciences) and Tianjin Genovo Biotechnology Co., Ltd. The patent covers six inventors and is classified under C12N 15/82 and C12N 9/22.

Optimized Protein Linkers and Methods of Use

The European Patent Office published patent EP4185699A1 for Pairwise Plants Services, Inc., covering optimized protein linkers and methods of use for plant biotechnology applications. The patent grants exclusive rights in 37 designated European member states and extension states. This is a standard patent publication granting intellectual property protection with no compliance obligations for third parties.

Immune Cells Overexpressing Cell Signaling Regulatory Factor and Use Thereof

The European Patent Office published patent application EP4105232A1 on March 25, 2026. The application covers engineered immune cells overexpressing cell signaling regulatory factors for therapeutic use. Applicants are Beijing Yongtai Ruike Biotechnology Company Ltd and Pharos Vaccine Inc. The filing is designated across 31 European states including DE, FR, GB, IT, and NL.

Generation of Diverse Viral Libraries - Patent Application EP4172324A1

The European Patent Office published patent application EP4172324A1 for Theolytics Ltd., titled 'Generation of Diverse Viral Libraries.' The invention, credited to inventor Margaret Duffy, relates to methods for creating diverse viral libraries with applications in pharmaceutical and biotechnology research. The patent designates all EU member states plus other European jurisdictions.

CELL CULTURE METHOD

The European Patent Office published patent application EP4092101A1 for AJINOMOTO CO., INC., covering a cell culture method. The patent was published March 25, 2026, with inventors OGawa Shimpei, Higuchi Takuya, Furomitsu Shumpei, Nishiyama Megumi, and Koseki Kotoe. The application covers C12M 3/00, C12N 5/02, C12N 5/074, and C12N 5/10 classifications and is designated across all EPC contracting states.

Low Alkaloid Nicotiana Plant Body Patent Granted

The European Patent Office granted Japan Tobacco Inc. Patent EP4136964A1 for a plant body of genus Nicotiana with low alkaloid content and its production method. The patent covers transgenic tobacco plants with modified alkaloid biosynthesis and methods for producing them. Designated states include all 31 EPC contracting states covering the EU, EEA, and other European countries.

Medicament Delivery Device with Feedback Signalling

The European Patent Office published patent application EP4233943A2 by SHL Medical AG for a medicament delivery device comprising feedback signalling means. The invention, classified under A61M 5/20 and A61M 5/315, covers devices for administering medicaments with user feedback functionality. This A2 publication indicates the application has entered the European regional phase and is available for opposition.